Bain Capital Life Sciences Investors as of March 31, 2024
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 26 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 19.9 | $248M | 11M | 23.65 | |
| Nuvalent Inc-a (NUVL) | 16.3 | $203M | 2.7M | 75.09 | |
| Dianthus Therapeutics (DNTH) | 7.2 | $90M | 3.0M | 30.00 | |
| Disc Medicine (IRON) | 6.6 | $82M | 1.3M | 62.26 | |
| Kyverna Therapeutics (KYTX) | 6.3 | $79M | 3.2M | 24.84 | |
| Pharvaris N V (PHVS) | 6.1 | $76M | 3.3M | 23.11 | |
| Savara (SVRA) | 5.8 | $73M | 15M | 4.98 | |
| Annexon (ANNX) | 5.0 | $62M | 8.7M | 7.17 | |
| Solid Biosciences Com New (SLDB) | 4.3 | $54M | 4.0M | 13.32 | |
| Madrigal Pharmaceuticals (MDGL) | 4.2 | $53M | 197k | 267.04 | |
| Mersana Therapeutics | 3.1 | $39M | 8.7M | 4.48 | |
| Cabaletta Bio (CABA) | 2.2 | $28M | 1.6M | 17.06 | |
| X4 Pharmaceuticals | 1.9 | $24M | 17M | 1.39 | |
| Tango Therapeutics (TNGX) | 1.8 | $23M | 2.9M | 7.94 | |
| Arcutis Biotherapeutics (ARQT) | 1.6 | $20M | 2.0M | 9.91 | |
| Nurix Therapeutics (NRIX) | 1.3 | $17M | 1.1M | 14.70 | |
| Syros Pharmaceuticals Com New (SYRS) | 1.2 | $15M | 2.7M | 5.35 | |
| Marinus Pharmaceuticals Com New | 1.0 | $13M | 1.4M | 9.04 | |
| Atea Pharmaceuticals (AVIR) | 0.8 | $10M | 2.5M | 4.04 | |
| C4 Therapeutics Com Stk (CCCC) | 0.7 | $9.3M | 1.1M | 8.17 | |
| Rapid Micro Biosystems Class A Com (RPID) | 0.7 | $8.2M | 8.4M | 0.97 | |
| Adagio Therapeutics (IVVD) | 0.6 | $8.0M | 1.8M | 4.44 | |
| Nautilus Biotechnology (NAUT) | 0.5 | $5.9M | 2.0M | 2.94 | |
| Aclaris Therapeutics (ACRS) | 0.3 | $3.7M | 3.0M | 1.24 | |
| Xilio Therapeutics (XLO) | 0.2 | $3.0M | 2.8M | 1.08 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $1.1M | 100k | 11.04 |
